2019 CRO Market Size & Growth Projections

Report Overview

2018 was a decent, not spectacular, year for CROs. We witnessed year-over-year revenue growth from all the major/public CROs. Yet, the major publicly traded CROs took a pause, along with the rest of the market. Remember, the S&P 500 fell by ~6% in 2018, so the fact that most of the public CROs managed to gain, is a win. The biopharmaceutical fundamentals stayed intact and CROs were able to take advantage.
ISR’s report gives quantitative insight into the perpetual question: “What is the size of the CRO market?” The data provide a thorough, rational perspective for clinical development services segmented by phase, geography, and service line.
ISR utilizes both publicly available information and data obtained through our syndicated primary market research efforts.

What you will learn:

• Estimated R&D expenditures through 2023
• Projected spending on development, Phase I-IV development, and outsourced Phase I-IV development through 2023, segmented by sponsor type:
  • Large pharma – large molecule
  • Large pharma – small molecule
  • Non-large pharma – large molecule
  • Non-large pharma – small molecule
  • Generic/Specialty
  • Government
  • Private
  • Association/Non-profit
  • Academic
• Spending on CRO services segmented by:
  • Geography
  • Service-line
  • Phase I-IV

Major Topics:

• Overall Market Size and Growth
• 2019 Geographic Assessment
• 2019 Service-line Assessment
• 2019 Development Phase I-IV Assessment
• 2018-2023 CRO Market Model
• 2018-2023 CRO Market Model – Growth Rates
• 2019 Public CRO Market Share